Entos Pharmaceuticals have announced that Entos has secured authorization from Health Canada to commence a phase 1/2 clinical study assessing Covigenix VAX-002.

The European Commission has authorized Roche's Alecensa as the inaugural and exclusive targeted adjuvant therapy for patients with early-stage ALK-positive lung cancer.

The FDA has approved Almirall’s Klisyri® (tirbanibulin) for treating actinic keratosis on facial or scalp areas up to 100 cm².

Lilly's tirzepatide outperformed placebo in resolving MASH, and over 50% of patients showed fibrosis improvement after 52 weeks.

EASL Conclusion Session Emphasized Novel Clinical Data on Unique HBV-targeted TCR T Cell Therapy (SCG101) Demonstrating Enhanced Survival Rates in HBV-linked Liver Cancer.

Geron Receives FDA Approval for RYTELO™ (imetelstat), a Novel Telomerase Inhibitor, to Treat Transfusion-Dependent Anemia in Adults with Lower-Risk MDS.

Annexon Reports Preliminary Success in Phase 3 Trial of Novel C1q Inhibitor ANX005 for Guillain-Barré Syndrome.

Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.

Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.

Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).